Why is Aarti Drugs Ltd ?
1
Company has a low Debt to Equity ratio (avg) at 0.44 times
2
With a growth in Net Profit of 65.11%, the company declared Very Positive results in Sep 26
- ROCE(HY) Highest at 13.74%
- DEBT-EQUITY RATIO(HY) Lowest at 0.37 times
- OPERATING PROFIT TO INTEREST(Q) Highest at 14.06 times
3
Stock is technically in a Bullish range
- The technical trend has improved from Mildly Bullish on 03-Nov-26 and has generated 4.07% returns since then
- Multiple factors for the stock are Bullish like MACD, Bollinger Band and OBV
4
With ROCE of 13.6, it has a Attractive valuation with a 2.2 Enterprise value to Capital Employed
- The stock is trading at a discount compared to its peers' average historical valuations
- Over the past year, while the stock has generated a return of 8.40%, its profits have risen by 15.7% ; the PEG ratio of the company is 1.2
5
Increasing Participation by Institutional Investors
- Institutional investors have increased their stake by 0.68% over the previous quarter and collectively hold 12.5% of the company
- These investors have better capability and resources to analyse fundamentals of companies than most retail investors
How much should you buy?
- Overall Portfolio exposure to Aarti Drugs should be less than 10%
- Overall Portfolio exposure to Pharmaceuticals & Biotechnology should be less than 30%
(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)
When to exit? - We will constantly monitor the company and suggest at the appropriate time to exit from the stock
Is Aarti Drugs for you?
High Risk, High Return
Absolute
Risk Adjusted
Volatility
Aarti Drugs
8.4%
0.23
35.87%
Sensex
-2.0%
-0.13
14.98%
Quality key factors
Factor
Value
Sales Growth (5y)
5.40%
EBIT Growth (5y)
1.38%
EBIT to Interest (avg)
8.14
Debt to EBITDA (avg)
1.86
Net Debt to Equity (avg)
0.36
Sales to Capital Employed (avg)
1.37
Tax Ratio
17.70%
Dividend Payout Ratio
5.43%
Pledged Shares
2.51%
Institutional Holding
12.50%
ROCE (avg)
13.97%
ROE (avg)
14.19%
Valuation Key Factors 
Factor
Value
P/E Ratio
19
Industry P/E
40
Price to Book Value
2.64
EV to EBIT
16.23
EV to EBITDA
13.13
EV to Capital Employed
2.20
EV to Sales
1.77
PEG Ratio
1.16
Dividend Yield
0.42%
ROCE (Latest)
13.57%
ROE (Latest)
13.70%
Loading Valuation Snapshot...
Technical key factors
Indicator
Weekly
Monthly
MACD
Bullish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bullish
Bullish
Moving Averages
Bullish (Daily)
KST
Mildly Bearish
Mildly Bullish
Dow Theory
No Trend
Mildly Bullish
OBV
Bullish
Bullish
Technical Movement
22What is working for the Company
ROCE(HY)
Highest at 13.74%
DEBT-EQUITY RATIO(HY)
Lowest at 0.37 times
OPERATING PROFIT TO INTEREST(Q)
Highest at 14.06 times
NET SALES(Q)
Highest at Rs 826.24 cr
PBDIT(Q)
Highest at Rs 135.36 cr.
OPERATING PROFIT TO NET SALES(Q)
Highest at 16.38%
PBT LESS OI(Q)
Highest at Rs 106.73 cr.
PAT(Q)
Highest at Rs 82.94 cr.
EPS(Q)
Highest at Rs 9.09
-1What is not working for the Company
NO KEY NEGATIVE TRIGGERS
Loading Valuation Snapshot...
Here's what is working for Aarti Drugs
Profit Before Tax less Other Income (PBT) - Quarterly
At Rs 106.73 cr has Grown at 87.1% (vs previous 4Q average)
over average PBT of the previous four quarters of Rs 57.06 CrMOJO Watch
Near term PBT trend is very positive
PBT less Other Income (Rs Cr)
Operating Profit to Interest - Quarterly
Highest at 14.06 times
in the last five quartersMOJO Watch
The company's ability to manage interest payments is improving
Operating Profit to Interest
Profit After Tax (PAT) - Quarterly
At Rs 82.94 cr has Grown at 72.2% (vs previous 4Q average)
over average PAT of the previous four quarters of Rs 48.17 CrMOJO Watch
Near term PAT trend is very positive
PAT (Rs Cr)
Debt-Equity Ratio - Half Yearly
Lowest at 0.37 times and Fallen
each half year in the last five half yearly periodsMOJO Watch
The company has been reducing its borrowing as compared to equity capital
Debt-Equity Ratio
Net Sales - Quarterly
Highest at Rs 826.24 cr
in the last five quartersMOJO Watch
Near term sales trend is positive
Net Sales (Rs Cr)
Net Sales - Quarterly
At Rs 826.24 cr has Grown at 23.4% (vs previous 4Q average)
over average Net Sales of the previous four quarters of Rs 669.40 CrMOJO Watch
Near term sales trend is positive
Net Sales (Rs Cr)
Operating Profit (PBDIT) - Quarterly
Highest at Rs 135.36 cr.
in the last five quartersMOJO Watch
Near term Operating Profit trend is positive
Operating Profit (Rs Cr)
Operating Profit Margin - Quarterly
Highest at 16.38%
in the last five quartersMOJO Watch
Company's efficiency has improved
Operating Profit to Sales
Profit Before Tax less Other Income (PBT) - Quarterly
Highest at Rs 106.73 cr.
in the last five quartersMOJO Watch
Near term PBT trend is positive
PBT less Other Income (Rs Cr)
Profit After Tax (PAT) - Quarterly
Highest at Rs 82.94 cr.
in the last five quartersMOJO Watch
Near term PAT trend is positive
PAT (Rs Cr)
Earnings per Share (EPS) - Quarterly
Highest at Rs 9.09
in the last five quartersMOJO Watch
Increasing profitability; company has created higher earnings for shareholders
EPS (Rs)
Here's what is not working for Aarti Drugs
Non Operating Income - Quarterly
Highest at Rs 2.55 cr
in the last five quartersMOJO Watch
Increased income from non business activities may not be sustainable
Non Operating Income